Andrew Pierce

Title: Andrew Pierce - Innovator in HER3 Targeting Antibodies

Introduction

Andrew Pierce is a notable inventor based in Milton, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target the HER3 receptor. His work has implications for diagnosing and treating diseases associated with HER3 mediated signal transduction.

Latest Patents

Andrew Pierce holds a patent titled "Binding molecules specific for HER3 and uses thereof." This patent includes antibodies and antigen binding fragments that bind to the extracellular domain of the HER3 receptor. These innovations inhibit various HER3 receptor-related functions through both ligand-dependent and ligand-independent mechanisms. Additionally, the patent describes compositions with increased half-life, as well as methods for diagnosing and treating diseases linked to HER3 signaling.

Career Highlights

Andrew is currently employed at MedImmune Limited, where he continues to advance his research in antibody development. His work is pivotal in the ongoing efforts to create effective therapies for diseases that involve HER3 signaling pathways.

Collaborations

Andrew has collaborated with notable colleagues such as Partha S Chowdhury and David Tice. Their combined expertise enhances the research and development efforts at MedImmune Limited.

Conclusion

Andrew Pierce's innovative work in HER3 targeting antibodies represents a significant advancement in biotechnology. His contributions are vital for the future of therapeutic interventions in diseases associated with HER3 signaling.